Bernadette Tansey
Bernadette Tansey has covered biotechnology, business, law, environment, and government as a Bay area journalist. She was a biotechnology reporter for the San Francisco Chronicle, where she also tracked the emerging fields of nanotechnology and synthetic biology. Bernadette studied neurobiology as a journalism fellow at Harvard Medical School, and learned about advances in medical devices during a National Press Club fellowship at UC San Diego. She was an environmental reporting fellow with the Institutes for Journalism and Natural Resources.
At the Stanford University Graduate School of Business, Bernadette served as a staff writing coach for an academic program in logic and communication for MBA students. She taught business journalism and reporting at San Francisco State University. Bernadette holds a BS in Biology from Syracuse University and a Master's degree in journalism from UC Berkeley.
Recent posts
-
Eight months after its public debut, Menlo Park, CA-based Calysta Energy has announced its first partnership deal. Calysta, a synthetic biology company, will attempt to engineer a new microbe that... Read more »
-
One of the main goals of California’s $3 billion stem cell research agency is to draw companies into the state so they can vie for a share of the funding.
With... Read more »
-
Words like “schizophrenia” and “bipolar disorder” have guided psychiatric treatment for decades, but they may be meaningless labels that mask a lack of real knowledge about the molecular events behind these... Read more »
-
Investing in biotechnology is a riskier bet these days. The community of life sciences venture capital firms is contracting, despite scientific advances across many fields like genomics, immunology, and diagnostics. Many... Read more »
-
Long before the explosion in the personal electronics field brought us iPods and iPhones, biomedical engineers were making devices to interact with the personal electrical “circuitry” that regulates the human heart... Read more »
-
Campuses at the University of Texas, such as the MD Anderson Cancer Center in Houston, can boast of star-studded faculties to rival the innovative scientific leadership at UC San Francisco, UC... Read more »
-
Few could accuse XBiotech CEO John Simard of failing to think big.
The Austin, TX-based startup he founded in 2005 is testing a novel biological drug candidate that is aiming to... Read more »
-
[Corrected 5/14/2013, 5:20 pm. See below.] Months before she received her PhD degree last spring, Jordan Kaufmann co-founded her own company. Her first office was a shed in her... Read more »
-
At one edge of the sprawling Texas Medical Center in south central Houston, near a slew of hospitals and research hubs including the renowned MD Anderson Cancer Center, three floors of... Read more »
-
Pharmaceutical companies have been fielding a slate of new drugs for multiple sclerosis in the past few years—most recently the new oral pill diethyl fumarate (Tecfidera) that analysts see as a... Read more »
-
One big story—the Boston Marathon bombing—dominated the news this week. Boston’s healthcare system rose to the challenge of treating so many injured victims, as reported in this terrific post by Atul... Read more »
-
Mehmet Toner wants cancer doctors to be able to see what he can see.
Most oncologists rely on imaging tools like CT scans, and perhaps only a single biopsy, to learn... Read more »
-
The Boston-area biotechnology cluster got a shot in the arm this week when a drug giant announced a major expansion. East Coast startups raised millions, or folded, or regrouped after significant... Read more »
-
New York-based Ziopharm Oncology (NASDAQ: ZIOP), which once seemed on the runway toward its first product approval for a relatively conventional cancer drug, is now buying itself time to sell... Read more »
-
The life sciences clusters around New York and Boston may sometimes act like rivals, but they also have plenty of reasons to work together. This week was marked by deals and... Read more »
-
Cambridge, MA-based Ra Pharmaceuticals has signed a collaboration deal with drug giant Merck (NYSE: MRK) that could provide the small company with as much as $200 million to support the development... Read more »
-
Biogen Idec reinforced its dominance in multiple sclerosis this week with the approval of its oral drug for the disease, while Third Rock Ventures amassed half a billion dollars more to... Read more »
-
The small Cambridge, MA-based company Dart Therapeutics has been racing along the startup track in recent months. In September, it assembled a veteran executive team headed by CEO Gene Williams, a Genzyme... Read more »
-
During this early spring week, it was a great time to focus on the fledgling efforts of East Coast drug hunters. A couple small companies pulled in lucrative partnerships, and two... Read more »
-
Drug developers have thrown an arsenal of technologies at tumor cells: nanomachines, vaccines, antibodies, radiation, you name it. David Scheinberg has tried them all in his search for new cancer therapies... Read more »
Page 1 of 3 next page »
